Compare BOH & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BOH | IRON |
|---|---|---|
| Founded | 1897 | 2017 |
| Country | | US |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.0B |
| IPO Year | N/A | 2020 |
| Metric | BOH | IRON |
|---|---|---|
| Price | $78.90 | $64.97 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 13 |
| Target Price | $80.40 | ★ $101.92 |
| AVG Volume (30 Days) | 483.7K | ★ 817.9K |
| Earning Date | 01-01-0001 | 04-14-2026 |
| Dividend Yield | ★ 3.54% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.66 | N/A |
| Revenue Next Year | $7.82 | N/A |
| P/E Ratio | $17.08 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $57.45 | $30.82 |
| 52 Week High | $80.61 | $99.50 |
| Indicator | BOH | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 64.30 | 38.81 |
| Support Level | $75.15 | $40.00 |
| Resistance Level | $80.25 | $73.97 |
| Average True Range (ATR) | 1.93 | 6.89 |
| MACD | 0.05 | -1.47 |
| Stochastic Oscillator | 74.64 | 57.00 |
Bank of Hawaii Corp provides a broad range of financial products and services predominantly to customers in Hawaii, Guam, and other Pacific Islands. The Bank's subsidiaries are engaged in equipment leasing, securities brokerage, investment advisory services, and providing credit insurance. It is organized into three business segments for management reporting purposes: Consumer Banking, Commercial Banking, and Treasury and Other. Majority of the revenue is generated from Consumer Banking segment which offers a broad range of financial products and services, including loan, deposit and insurance products; private banking and international client banking services; trust services; investment management; and institutional investment advisory services.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.